AU2012345659B2 - Acamprosate formulations, methods of using the same, and combinations comprising the same - Google Patents

Acamprosate formulations, methods of using the same, and combinations comprising the same Download PDF

Info

Publication number
AU2012345659B2
AU2012345659B2 AU2012345659A AU2012345659A AU2012345659B2 AU 2012345659 B2 AU2012345659 B2 AU 2012345659B2 AU 2012345659 A AU2012345659 A AU 2012345659A AU 2012345659 A AU2012345659 A AU 2012345659A AU 2012345659 B2 AU2012345659 B2 AU 2012345659B2
Authority
AU
Australia
Prior art keywords
acamprosate
tablet
disorder
neuroleptic
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012345659A
Other languages
English (en)
Other versions
AU2012345659A8 (en
AU2012345659A1 (en
Inventor
San-Laung Chow
Barry S. Fogel
Kei-Lai FONG
William D. Kerns
Edward Lin
David Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synchroneuron Inc
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Publication of AU2012345659A1 publication Critical patent/AU2012345659A1/en
Publication of AU2012345659A8 publication Critical patent/AU2012345659A8/en
Application granted granted Critical
Publication of AU2012345659B2 publication Critical patent/AU2012345659B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2012345659A 2011-12-02 2012-12-02 Acamprosate formulations, methods of using the same, and combinations comprising the same Active AU2012345659B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161566550P 2011-12-02 2011-12-02
US61/566,550 2011-12-02
US201261649137P 2012-05-18 2012-05-18
US61/649,137 2012-05-18
PCT/US2012/067507 WO2013082573A1 (en) 2011-12-02 2012-12-02 Acamprosate formulations, methods of using the same, and combinations comprising the same

Publications (3)

Publication Number Publication Date
AU2012345659A1 AU2012345659A1 (en) 2014-07-24
AU2012345659A8 AU2012345659A8 (en) 2014-08-07
AU2012345659B2 true AU2012345659B2 (en) 2017-09-28

Family

ID=48536156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012345659A Active AU2012345659B2 (en) 2011-12-02 2012-12-02 Acamprosate formulations, methods of using the same, and combinations comprising the same

Country Status (14)

Country Link
EP (1) EP2785337B1 (enExample)
JP (1) JP6407720B2 (enExample)
KR (1) KR102055859B1 (enExample)
CN (1) CN104379138B (enExample)
AU (1) AU2012345659B2 (enExample)
BR (1) BR112014013374B1 (enExample)
CA (1) CA2863265C (enExample)
HK (2) HK1199841A1 (enExample)
IL (1) IL232935B (enExample)
MX (1) MX375183B (enExample)
RU (1) RU2671399C2 (enExample)
SG (1) SG11201403785UA (enExample)
WO (1) WO2013082573A1 (enExample)
ZA (1) ZA201404826B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2016520653A (ja) * 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
EP3946303A4 (en) * 2019-04-03 2022-12-14 Synchroneuron Inc. FORMULATING
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021069504A1 (en) * 2019-10-11 2021-04-15 F. Hoffmann-La Roche Ag Drug dosage determination devices and methods
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426087B1 (en) * 1998-02-23 2002-07-30 Merck Patent Gesellschaft Mit Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent
WO2012050922A2 (en) * 2010-09-28 2012-04-19 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047436B1 (en) * 1998-01-13 2009-10-21 Synchroneuron, LLC N-acetylhomotaurinates for use in treating hyperkinesias
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
RU2284814C1 (ru) * 2005-04-08 2006-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
TW201200165A (en) * 2010-02-22 2012-01-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426087B1 (en) * 1998-02-23 2002-07-30 Merck Patent Gesellschaft Mit Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent
WO2012050922A2 (en) * 2010-09-28 2012-04-19 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract

Also Published As

Publication number Publication date
EP2785337A1 (en) 2014-10-08
BR112014013374B1 (pt) 2022-10-11
RU2014126879A (ru) 2016-01-27
BR112014013374A2 (pt) 2017-06-13
IL232935B (en) 2020-11-30
WO2013082573A1 (en) 2013-06-06
MX375183B (es) 2025-03-06
JP2015500812A (ja) 2015-01-08
AU2012345659A8 (en) 2014-08-07
IL232935A0 (en) 2014-07-31
CA2863265A1 (en) 2013-06-06
ZA201404826B (en) 2016-07-27
HK1199841A1 (en) 2015-07-24
EP2785337B1 (en) 2021-01-20
CN104379138A (zh) 2015-02-25
JP6407720B2 (ja) 2018-10-17
BR112014013374A8 (pt) 2021-08-31
HK1207563A1 (en) 2016-02-05
CN104379138B (zh) 2021-12-07
KR102055859B1 (ko) 2019-12-13
RU2671399C2 (ru) 2018-10-31
CA2863265C (en) 2020-04-14
EP2785337A4 (en) 2015-04-22
MX2014006574A (es) 2015-02-10
SG11201403785UA (en) 2014-10-30
KR20140121394A (ko) 2014-10-15
AU2012345659A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
US10512621B2 (en) Methods of treating posttraumatic stress disorder with acamprosate salts
US20150250746A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
US20090028941A1 (en) Pulsatile gastric retentive dosage forms
EP2785337B1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2012500221A (ja) Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
CA2850468A1 (en) Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
MX2008010578A (es) Formulacion de niacina de bajo enrojecimiento.
AU2012277375A1 (en) Multilayered dosage form
TW200520748A (en) Modafinil modified release pharmaceutical compositions
US20070134322A1 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
US20070112075A1 (en) Stable pharmaceutical formulations containing escitalopram and bupropion
JP2016518406A (ja) 嗜癖障害およびアルコール関連障害を治療するための（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］へキサンの使用
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 29 , PAGE(S) 3949 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SYNCHRONEURON INC., APPLICATION NO. 2012345659, UNDER INID (72) ADD CO-INVENTORS CHOW, SAN-LAUNG; WONG, DAVID; LIN, EDWARD

FGA Letters patent sealed or granted (standard patent)